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ABSTRACT 120 Patients from North Jordan were screened for three cystic fibrosis mutations; “F508, W1282X,
and N1303K. This study identified “F508 (23.75%) and W1282X (15%) only. N1303K was not detected, although
it was reported earlier from Jordan in low frequency.
INTRODUCTION
Cystic fibrosis (CF) is the most common lethal
genetic disorder among Caucasian population;
it affects 1 in 2500 live births (Kambouris 2000).
It is an autosomal recessive diseases that arises
due to mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR)
gene on chromosome 7q 31.2 (Welsh et al. 1995).
Those mutations produce abnormal cystic
fibrosis transmembrane conductance regulator,
which functions as a chloride channel. This
impairs water movement across epithelia and lead
to formation of viscous mucus that obstructs
the airways of the lungs and ducts of the pancreas
(Cutting et al. 1990). On the other hand,
dysfunction of the CFTR elevates sodium and
chloride concentration in sweat, and almost all
males are infertile due to bilateral absence of vas
deferens (Jacobson et al. 1993).The first CF
mutation described is known as “F508, this is
the most common mutation in Northern European
derived populations including the United States
and accounts for 70-75% of CF chromosomes
(Kerem et al. 1989; Lemna et al. 1990).
CF shows high heterogeneity among
patients; some phenotypic variations correlated
with the type of mutation present in CFTR gene.
Moreover, it was shown that frequencies of CF
mutations are variable among different ethnic
population (Eitan Kerem et al. 1995)
According to CF mutation database, more
than 1000 mutations have been identified until
now. The most common one is “F508, which
includes deletion of phenylalanine at positions
508 of protein containing 1480 amino acids and
account for 67 % of Caucasian CF chromosome
world-wide (Welsh et al. 1995). It has been
reported that CF occurs in non-Caucasian
populations but is less common than Caucasian
(Cutting 1997). Although CF is considered very
rare in many races including Arabs, this is
probably due to a lack of careful surveys and
screening programmers (Nazer 1986; Ginsberg et
al. 1994).
The aim of this study was to identify the
frequency of three common CF mutations (“F508,
W1282X, N1303K) among Jordanian CF patients
in North Jordan population for possible use in a
nation wide screening program for CF.
MATERIAL  AND  METHODS
Peripheral blood samples from 120 CF patients
(sweat chloride > 60 mmol/L diagnostic of CF
and clinical symptoms characteristic of CF) in
King Abdullah university hospital and Princes
Rahmah Teaching Hospital in Irbid (North Jordan)
were collected in EDTA tubes. All patients were
fully informed that their blood would be used for
molecular investigation of the CFTR gene
mutations and consent was obtained from each
patient or his/her guardians.
DNA extraction was carried out using salt
precipitation method with purification kit
provided by Promega, USA (Miller et al. 1988).
Samples were screened for mutations using
ARMS PCR (Amplification Refractory Mutation
System- PCR). This method is rapid, reliable,
nonisotopic and results can be easily obtained
Address for Correpondence: Dr. Fawzi Alsheyab
Department  of Biotechnology & Genetic Engineering
Jordan University of Science and Technology, P.O. Box
3030, Irbid  21100, Jordan
Fax: 00962 2 7095014
E-mail:  fawzish@just.edu.jo138 F. AL SHEYAB, S. M.  BALLAT AND M. RAWASHDEH
within one working day. For each mutation there
are three primers (a common primer, a normal
primer and the mutant primer). The forward primer
is the common primer (C), whereas the reverse
primer is designed to either anneal and to amplify
the mutant (M) or the wild type in allele. A typical
ARMS test consists of two complementary
reactions:  the first reaction contains an ARMS
primer specific for the normal DNA sequence and
cannot amplify mutant DNA at a given locus.
Similarly, the second reaction contains a mutant
specific primer and does not amplify normal DNA.
Table 1 includes primers which were used for
mutations detection (Ferrie et al. 1992; Newton
et al. 1989). DNA bands stained with ethidium
bromide and localized using Polaroid camera
(Polaroid 677).
The genotype of each individual was
determined by analysis of the amplification
product. A normal individual generate PCR
product only in normal reaction; a heterozygous
gives products in both reaction, and the
homozygous mutant does so only in the mutant
reaction.
RESULTS
120 CF patients were screened for CF
mutations; (“F508, W1282X, and N1303K). The
frequency of  “F508 was the most common
mutation among Jordanian CF patients with a
frequency of  23.75% followed by W1282X with
a frequency  of 15 % where as N1303K was not
detected in our samples. Table  2 summarizes the
frequencies of those mutations.
The genotype of each individual was
determined based on the analysis of the
amplification product. Table 3 summarizes the
genotype result.
 DISCUSSION
The first report about cystic fibrosis in
Jordan appeared in 1984, in which 12 patients were
diagnosed after postmortem examination (Nazer
1984). In neonatal screening including 7682
neonates for CF from 10 hospitals using meconium
albumin method, the incidence was calculated as
1 per 2560 live births (Hisham M. Nazer 1992). The
present study demonstrates the prevalence of
mutations in north Jordan by determining the
frequency of CF mutation mainly in affected
individuals in contrast with the previous study
that was a population based study.
Our findings indicate that, “F508 mutation is
the most common among CF patients in North
Jordan (23.75%) followed by W1282X mutation
with 15% where as N1303K was not detected in
our samples.  The distribution of mutations has
Table 2: Frequencies of three mutations detected
in CF Patients in North Jordan
Mutation No. of  chromosomes %
 carry CF allele
“F508 57/240 23.75
W1282X 36/240 15.00
N1303K 0/240 0.00
unknown 147/240 61.25
Total 240/240 100.00
Table 3:  Frequency of the observed genotypes (total
120) cystic fibrosis patients in North Jordan
Genotype No. of %
patients
“F508/”F508 13 10.83
“F508/unidentified 33 27.5
“F508/W1282X 11 9.17
W1282X/unidentified 25 20.83
Unidentified/unidentified 38 31.66
Total 120 100.00
Table 1:  Sequences of primers used in ARMS reactions
Mutation Sequence 5N—3N— Size bp
“F508
Common primer GACTTCACTTCTAATGATGATTATGGGAGA
Normal primer GTATCTATATTCATCATAGGAAACACCACA 160
Mutant primer GTATCTATATTCATCATAGGAAACACCATT 157
W1282X
Common primer CCCATCACTTTTACCTTATAGGTGGGCCTC
Normal primer CCTGTGGTATCACTCCAAAGGCTTTCCAC 178
Mutant primer CCTGTGGTATCACTCCAAAGGCTTTCCAT 178
N1303K
Common primer CTCAATTTCTTTATTCTAAAGACATTGG
Normal primer GATCACTCCACTGTTCATAGGGATCCAAG 328
Mutant primer GATCACTCCACTGTTCATAGGGATCCAAC 328RELATIVE FREQUENCIES OF THREE CYSTIC FIBROSIS MUTATIONS IN NORTH JORDAN 139
Table 4: Frequencies of CF mutation in the neighboring countries.
“F508 W1282X N1303K Reference
Jordan 23.75% 15% 0.00% Present study
Israel 29.40% - 2.70% Orgad et al. 2001
Turkey 27% 0.60% 1.80% Onay et al. 1998 & 2001
Lebanon 37.50% 15.60% 9.40% Desgeorges et al. 1997
Tunis 17.90% 2.50% 6.40% Taieb et al. 1996
Iran 16.20% 4.00% - Jalalirad M et al. 2004
Saudi Arabia 15% 3.00% - Desgeorges et al. 1997
now been established in many populations of
various ethnic groups, where as “F508 was the
most common mutation with a frequency of 66%
world-wide. Its relative frequency varies between
north and south of Europe (“F508 account for
90% of CF chromosomes in Denmark, and 30% in
Turkey) [Cystic Fibrosis Genetic Analysis
Consortium, pers.commun].
Our results are slightly different from those
reported from neighboring countries for the three
mutations (“F508, W1282X, and N1303K) as seen
in Table 4. CF mutations and their relative
frequencies observed in our samples are within
the range as reported from other neighboring
countries which various for the “F508 mutation
from 37.5% among Lebanese patients
(Desgeorges et al. 1997) to 15% observed in Saudi
Arabia (Desgeorges et al. 1997), from 15.6% in
Lebanese patients (Desgeorges et al. 1997) to
0.6% in Turkish patients (Onay et al. 1998, 2001)
for W1282X mutation and form 9.4% in Lebanese
patients to 1.8% (Desgeorges et al. 1997) in
Turkish patients (Onay et al. 1998, 2001) for
N1303K mutation. These differences could be
partially explained by variation in the diagnostic
criteria among each study (Gerardo et al. 2002),
and evidence of declining frequency of these
mutations in a north-west to south-east direction
Europe has been mapped (Yilmaz et al. 1990;
European Working Group on CF Genetics 1990)
which may applied to the our region (middle east)
which is located to south-east of Europe.
CONCLUSION
Further studies of larger samples from
different geographical locations of Jordan should
be undertaken to better understand the pre-
valence of CF among the Jordanian population.
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